1.Dakin HA, Gray A. Economic evaluation of factorial randomised controlled trials: Challenges, methods and recommendations. Statistics in Medicine 2017, 36(18):2814–2830. https://doi.org/10.1002/sim.7322.
2.Dakin HA, Gray A. Decision-making for healthcare resource allocation: Joint versus separate decisions on interacting interventions. Medical Decision Making 2018, 38(4):476–486. https://doi.org/10.1177/0272989X18758018.
3.Hung HM, Chi GY, O’Neill RT. Efficacy evaluation for monotherapies in two-by-two factorial trials. Biometrics 1995, 51(4):1483–1493.
4.Hung HM. Two-stage tests for studying monotherapy and combination therapy in two-by-two factorial trials. Stat Med 1993, 12(7):645–660.
5.Montgomery AA, Peters TJ, Little P. Design, analysis and presentation of factorial randomised controlled trials. BMC Med Res Methodol 2003, 3:26. https://doi.org/10.1186/1471–2288–3–26.
6.Brittain E, Wittes J. Factorial designs in clinical trials: the effects of non-compliance and subadditivity. Stat Med 1989, 8(2):161–171.
7.Green S: Factorial designs with time to event endpoints. In: Handbook of Statistics in Clinical Oncology. Second edn. Edited by Crowley J, Ankerst DP. Boca Raton, FL: Chapman & Hall/CRC; 2006: 181–189.
8.Claxton K. The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. Journal of health economics 1999, 18(3):341–364. https://doi.org/10.1016/S0167–6296(98)00039–3.
9.McAlister FA, Straus SE, Sackett DL, Altman DG. Analysis and reporting of factorial trials: a systematic review. JAMA 2003, 289(19):2545–2553. https://doi.org/10.1001/jama.289.19.2545.
10.Brown J, Welton NJ, Bankhead C, Richards SH, Roberts L, Tydeman C, Peters TJ. A Bayesian approach to analysing the cost-effectiveness of two primary care interventions aimed at improving attendance for breast screening. Health Econ 2006, 15(5):435–445. https://doi.org/10.1002/hec.1077.
11.Welton NJ, Ades AE, Caldwell DM, Peters TJ. Research prioritization based on expected value of partial perfect information: a case-study on interventions to increase uptake of breast cancer screening. J R Statist Soc A 2008, 171(Part 4):807–841.
12.Welton NJ, Madan JJ, Caldwell DM, Peters TJ, Ades AE. Expected Value of Sample Information for Multi-Arm Cluster Randomized Trials with Binary Outcomes. Med Decis Making 2013, 34:352–365. https://doi.org/10.1177/0272989X13501229.
13.United Kingdom back pain exercise and manipulation (UK BEAM) randomised trial: cost effectiveness of physical treatments for back pain in primary care. BMJ 2004, 329(7479):1381. https://doi.org/bmj.38282.607859.AE.
14.Boyle J, McCartney E, Forbes J, O’Hare A. A randomised controlled trial and economic evaluation of direct versus indirect and individual versus group modes of speech and language therapy for children with primary language impairment. Health Technol Assess 2007, 11(25):iii-iv, xi-xii, 1–139. https://doi.org/99/36/04 [pii].
15.Hollinghurst S, Sharp D, Ballard K, Barnett J, Beattie A, Evans M, Lewith G, Middleton K, Oxford F, Webley F et al. Randomised controlled trial of Alexander technique lessons, exercise, and massage (ATEAM) for chronic and recurrent back pain: economic evaluation. BMJ 2008, 337:a2656.
16.Reddy P, Kalus JS, Caron MF, Horowitz S, Karapanos A, Coleman CI, Kluger J, White CM. Economic analysis of intravenous plus oral amiodarone, atrial septal pacing, and both strategies to prevent atrial fibrillation after open heart surgery. Pharmacotherapy 2004, 24(8):1013–1019.
17.Foster EM, Jensen PS, Schlander M, Pelham WE, Jr., Hechtman L, Arnold LE, Swanson JM, Wigal T. Treatment for ADHD: is more complex treatment cost-effective for more complex cases? Health Serv Res 2007, 42(1 Pt 1):165–182. https://doi.org/HESR599.
18.Hollis JF, McAfee TA, Fellows JL, Zbikowski SM, Stark M, Riedlinger K. The effectiveness and cost effectiveness of telephone counselling and the nicotine patch in a state tobacco quitline. Tobacco Control 2007, 16 Supplement(1):i53-i59.
19.StataCorp: sureg—Zellner’s seemingly unrelated regression. In: Stata Base Reference Manual: Release 11. Volume Volume 3, Q-Z, edn. College Station, TX: StataCorp LP; 2009: 2100–2107.
20.National Institute for Health and Care Excellence. Guide to the methods of technology appraisal 2013. http://www.nice.org.uk/media/D45/1E/GuideToMethodsTechnologyAppraisal2013.pdf. Accessed 17th May 2013.
21.Piantadosi S: Chapter 19: Factorial trials. In: Clinical trials: a methodological perspective. Second edn. Hoboken, NJ: John Wiley & Sons Inc; 2005: 501–513.
22.Frempong SN, Goranitis I, Oppong R. Economic evaluation alongside factorial trials: a systematic review of empirical studies. Expert Rev Pharmacoecon Outcomes Res 2015, 15(5):801–811. https://doi.org/10.1586/14737167.2015.1076336.
23.Campbell AJ, Robertson MC, La Grow SJ, Kerse NM, Sanderson GF, Jacobs RJ, Sharp DM, Hale LA. Randomised controlled trial of prevention of falls in people aged > = 75 with severe visual impairment: the VIP trial. BMJ 2005, 331(7520):817.
24.Sevick MA, Miller GD, Loeser RF, Williamson JD, Messier SP. Cost-effectiveness of exercise and diet in overweight and obese adults with knee osteoarthritis. Med Sci Sports Exerc 2009, 41(6):1167–1174. https://doi.org/10.1249/MSS.0b013e318197ece7.
25.Salize HJP, Merkel SD-R, Reinhard ID-M, Twardella DP, Mann KMD, Brenner HMDMPH. Cost-effective Primary Care-Based Strategies to Improve Smoking Cessation: More Value for Money. Archives of Internal Medicine 2009, 169(3):230–235.
26.Lamb SE, Gates S, Underwood MR, Cooke MW, Ashby D, Szczepura A, Williams MA, Williamson EM, Withers EJ, Mt Isa S et al. Managing Injuries of the Neck Trial (MINT): design of a randomised controlled trial of treatments for whiplash associated disorders. BMC Musculoskelet Disord 2007, 8:7. https://doi.org/1471–2474–8–7.
27.Ng T. The impact of a preliminary test for interaction in a 2 x 2 factorial trial. Proceedings of the Biopharmaceutical Section of the American Statistical Association, Alexandria, VA 1991:220–227.
28.Simon R, Freedman LS. Bayesian design and analysis of two x two factorial clinical trials. Biometrics 1997, 53(2):456–464.
29.Briggs A. Economic evaluation and clinical trials: size matters. Bmj 2000, 321(7273):1362–1363.
30.Backhouse ME. Use of randomised controlled trials for producing cost-effectiveness evidence: potential impact of design choices on sample size and study duration. Pharmacoeconomics 2002, 20(15):1061–1077. https://doi.org/201503 [pii].
31.Ramsey S, Willke R, Briggs A, Brown R, Buxton M, Chawla A, Cook J, Glick H, Liljas B, Petitti D et al. Good Research Practices for Cost-Effectiveness Analysis Alongside Clinical Trials: The ISPOR RCT-CEA Task Force Report. Value Health 2005, 8(5):521–533.
32.Hollingworth W, McKell-Redwood D, Hampson L, Metcalfe C. Cost utility analysis conducted alongside RCTs: Is inefficiency considered in sample size calculations? Poster presented at the MRC Clinical Trials Methodology Conference, Bristol, UK, 4th–5th October 2011 2011
33.Anderson P, Lloyd A: Outcomes research and health economics. In: Principles of Clinical Research. edn. Edited by Di Giovanna I, Hayes G. Stroud, UK: Wrightson Biomedical Publishing Ltd; 2001: 291–316.
34.Marshall DA, Hux M. Design and analysis issues for economic analysis alongside clinical trials. Med Care 2009, 47(7 Suppl 1):S14–20. https://doi.org/10.1097/MLR.0b013e3181a31971.
35.O’Brien B. Economic evaluation of pharmaceuticals. Frankenstein’s monster or vampire of trials? Med Care 1996, 34(12 Suppl):DS99–108.
36.Byar DP. Factorial and reciprocal control designs. Stat Med 1990, 9(1–2):55–63; discussion 63–54.
37.Byar DP, Piantadosi S. Factorial designs for randomized clinical trials. Cancer Treat Rep 1985, 69(10):1055–1063.
38.Yates F. Complex experiments (with discussion). J Roy Statist Soc 1935, B2:181–247.
39.Burnham KP, Anderson DR. Multimodel Inference: Understanding AIC and BIC in Model Selection. Sociological Methods and Research 2004, 33(2):261–304. https://doi.org/10.1177/0049124104268644.
40.Lancelot R, Lesnoff M, McDermott JJ. Use of Akaike information criteria for model selection and inference: An application to assess prevention of gastrointestinal parasitism and respiratory mortality of Guinean goats in Kolda, Senegal. Preventive Veterinary Medicine 2002, 55(4):217–240.